Acalabrutinib (Tablets) Monotherapy
Indication
00840a
As monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00840b
As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy
Bendamustine Monotherapy
Indication
00527a
Treatment of patients with relapsed or refractory Chronic Lymphocytic Leukaemia (CLL)
Chlorambucil 10mg/m2 Therapy
Fludarabine, cycloPHOSphamide and riTUXimab ( FC (IV) and R) Therapy
Ibrutinib Therapy-CLL - Waldenström’s macroglobulinaemia
Indication
00296a
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.
00296b
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
Idelalisib and riTUXimab Therapy
Indication
00389a
In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00389b
In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies
Obinutuzumab and Chlorambucil Therapy
Indication
00286a
Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.
Venetoclax Monotherapy
Indication
00400a
Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.
00400b
Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor
Venetoclax and Obinutuzumab Therapy
Indication
00715a
In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Venetoclax and riTUXimab Therapy
Indication
00575a
Venetoclax in combination with riTUXimab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
Zanubrutinib Therapy
Indication
00708b
As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), who are treatment naïve and have del(17p) and/or TP53-mutated disease
00708c
As monotherapy for the treatment of adult patients with CLL, who have relapsed and/or refractory disease following at least one line of prior therapy
Cladribine 0.14mg/day Day 1 to 5 Therapy
Cladribine 0.14mg/day Day 1 to 5 Therapy
Cladribine Weekly and riTUXimab Therapy
Indication
00534a
Treatment for adult patients with relapsed or partially responsive Hairy Cell Leukaemia.
Cladribine 5 day and riTUXimab Therapy
Indication
00531a
Treatment for adult patients with relapsed or partially responsive Hairy Cell Leukaemia.